It’s been a crucial week for Pacira BioSciences, Inc. (NASDAQ:PCRX); here’s what analysts have to say.

Pacira BioSciences, Inc. (NASDAQ:PCRX) Logo
Investors sentiment increased to 1.59 in Q2 2019. Its up 0.18, from 1.41 in 2019Q1. It increased, as 20 investors sold Pacira BioSciences, Inc. shares while 46 reduced holdings. 41 funds opened positions while 64 raised stakes. 40.17 million shares or 30.83% less from 58.08 million shares in 2019Q1 were reported.
15,648 are owned by Stephens Inc Ar. Gsa Prtnrs Limited Liability Partnership owns 36,043 shares for 0.18% of their portfolio. Public Employees Retirement Association Of Colorado invested in 0.11% or 425,660 shares. Numerixs Inv Techs stated it has 0.04% in Pacira BioSciences, Inc. (NASDAQ:PCRX). D E Shaw Com Inc holds 0.07% of its portfolio in Pacira BioSciences, Inc. (NASDAQ:PCRX) for 1.25M shares. J Goldman & Limited Partnership reported 90,418 shares stake. Art Advisors Limited Com accumulated 12,526 shares. Northern Trust owns 523,603 shares. Proshare Advsrs Ltd holds 0% or 16,276 shares. The New York-based Prelude Capital Limited Com has invested 0.04% in Pacira BioSciences, Inc. (NASDAQ:PCRX). Natl Asset Management invested 0.02% of its portfolio in Pacira BioSciences, Inc. (NASDAQ:PCRX). 500,069 were accumulated by Elk Creek Prtnrs Limited Com. Manufacturers Life Ins Company The accumulated 25,382 shares or 0% of the stock. Adirondack Trust Communication holds 0.02% or 600 shares in its portfolio. Boston Private Wealth Ltd has invested 0.01% in Pacira BioSciences, Inc. (NASDAQ:PCRX).

Pacira BioSciences, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 2 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Pacira Pharmaceuticals has $85 highest and $2900 lowest target. $52.33’s average target is 37.71% above currents $38 stock price. Pacira Pharmaceuticals had 4 analyst reports since May 6, 2019 according to SRatingsIntel. BMO Capital Markets maintained the shares of PCRX in report on Friday, August 9 with “Market Perform” rating. The firm earned “Buy” rating on Tuesday, June 25 by Wedbush. Below is a list of Pacira BioSciences, Inc. (NASDAQ:PCRX) latest ratings and price target changes.

09/08/2019 Broker: BMO Capital Markets Rating: Market Perform Old Target: $46.0000 New Target: $43.0000 Maintain
25/06/2019 Broker: Wedbush Rating: Buy New Target: $85 Maintain
11/06/2019 Broker: Inc. – Common Stock Rating: Barclays 52.0000
06/05/2019 Broker: Inc. – Common Stock Rating: Mizuho New Target: $29.0000 38.0000

The stock increased 2.01% or $0.75 during the last trading session, reaching $38. About 320,900 shares traded. Pacira BioSciences, Inc. (NASDAQ:PCRX) has risen 9.59% since September 13, 2018 and is uptrending. It has outperformed by 9.59% the S&P500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.58 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It has a 206.59 P/E ratio. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

More notable recent Pacira BioSciences, Inc. (NASDAQ:PCRX) news were published by: Globenewswire.com which released: “Pacira Announces Publication of Pivotal Study of EXPAREL as a Single-Dose Interscalene Brachial Plexus Nerve Block in Patients Undergoing Shoulder Surgery – GlobeNewswire” on June 04, 2019, also Seekingalpha.com with their article: “Heron’s HTX-011 pain is Pacira’s gain, up 16% premarket – Seeking Alpha” published on May 01, 2019, Seekingalpha.com published: “EMA accepts Pacira’s application for Exparel for postsurgical pain – Seeking Alpha” on June 25, 2019. More interesting news about Pacira BioSciences, Inc. (NASDAQ:PCRX) were released by: Seekingalpha.com and their article: “Pacira Pharmaceuticals Q1 2019 Earnings Preview – Seeking Alpha” published on May 01, 2019 as well as Finance.Yahoo.com‘s news article titled: “Should You Be Concerned About Pacira BioSciences, Inc.’s (NASDAQ:PCRX) Historical Volatility? – Yahoo Finance” with publication date: July 31, 2019.

Pacira BioSciences, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.